ClinicalTrials.gg

Program

elismetrep

Also written as “MT-8554”, “Elismetrep” and “MT-8554 low dose”.

Its studies are mostly in Migraine Disorders · Hot Flashes, led by 2 companies.

Furthest: phase 3, since May 29, 201714 company-led studies, 3 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tanabe Pharma100 open or runningphase 2since May 29, 2017Apr 16, 2015none ahead
TriGemX Bio43 open or runningphase 3since Jun 9, 2026Feb 21, 2025Feb 2027phase 3 · NCT07645924

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2015First study: phase 1 study in HealthyNew to Tanabe PharmaTanabe Pharma · NCT02429102 · 135 enrolled · United Kingdom
  2. Aug 16, 2015Phase 1 study in HealthyTanabe Pharma · NCT02536209 · 20 enrolled · United Kingdom
  3. Feb 3, 2016Phase 1 study in HealthyTanabe Pharma · NCT02675309 · 28 enrolled · United Kingdom
  4. Jun 14, 2016Phase 1 study in Vasomotor SymptomsTanabe Pharma · NCT02803268 · 24 enrolled · Germany
  5. May 29, 2017Phase 2 study in Painful Diabetic Peripheral NeuropathyTanabe Pharma · NCT03172598 · 61 enrolled · Germany, Hungary, Poland
  6. Sep 20, 2017Phase 2 study in Menopause Hot FlashesTanabe Pharma · NCT03291067 · 375 enrolled · United States
  7. Nov 29, 2017Phase 1 study in Healthy VolunteerTanabe Pharma · NCT03381404 · 6 enrolled · United Kingdom
  8. Feb 28, 2018Phase 1 study in Healthy VolunteerTanabe Pharma · NCT03471130 · 48 enrolled · United Kingdom
  9. Mar 29, 2018Phase 2 study in Vasomotor Symptoms (VMS)Tanabe Pharma · NCT03541200 · 190 enrolled · United States
  10. Oct 18, 2021Phase 2 study in Painful Diabetic Peripheral NeuropathyTanabe Pharma · NCT05123196 · 156 enrolled · Japan
  11. Feb 21, 2025TriGemX Bio's first study: phase 2 study in Migraine DisordersNew to TriGemX BioTriGemX Bio · NCT06848075 · 431 enrolled · United States
  12. Jun 9, 20262 phase 3 studiesPhase 3 reachedTriGemX Bio · NCT07645924, NCT07674654
  13. Sep 7, 2026Phase 3 study in Migraine DisordersTriGemX Bio · NCT07816367 · 1,500 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 3 study in Migraine DisordersTriGemX Bio · NCT07645924
  2. Oct 2027Primary completion: phase 3 study in Migraine DisordersTriGemX Bio · NCT07816367
  3. Jun 2028Primary completion: phase 3 study in Acute MigraineTriGemX Bio · NCT07674654

TargetBeta

TRPM8 →read by rule
“Transient receptor potential cation channel subfamily M member 8 inhibitor”ChEMBL 37, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07816367Migraine Disorders · United States3RecruitingTriGemX BioOct 20271,500
NCT07674654Acute Migraine · United States3RecruitingTriGemX BioJun 20281,000
NCT07645924Migraine Disorders · United States3RecruitingTriGemX BioFeb 20271,800
NCT06848075Migraine Disorders · United States2CompletedTriGemX BioAug 4, 2025431
NCT05123196Painful Diabetic Peripheral Neuropathy · Japan2CompletedTanabe PharmaNov 1, 2022156
NCT03541200Vasomotor Symptoms (VMS) · United States2CompletedTanabe PharmaNov 15, 2019190
NCT03471130Healthy Volunteer · United Kingdom1CompletedTanabe PharmaOct 19, 201848
NCT03381404Healthy Volunteer · United Kingdom1CompletedTanabe PharmaJan 29, 20186
NCT03291067Menopause Hot Flashes · United States2CompletedTanabe PharmaOct 19, 2018375
NCT03172598Painful Diabetic Peripheral Neuropathy · Germany, Hungary, Poland2CompletedTanabe PharmaAug 8, 201861
NCT02803268Vasomotor Symptoms · Germany1CompletedTanabe PharmaJan 201724
NCT02675309Healthy · United Kingdom1CompletedTanabe PharmaMar 201628
NCT02536209Healthy · United Kingdom1CompletedTanabe PharmaNov 201520
NCT02429102Healthy · United Kingdom1CompletedTanabe PharmaNov 2015135

How it is read

Names in the registry

  • “MT-8554”, 4 entries
  • “Elismetrep”, 3 entries
  • “MT-8554 low dose”, 3 entries
  • “MT-8554 high dose”, 3 entries
  • “MT-8554 middle dose”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.